CD69 and myeloid sarcoma: Importantly, comparing stimulated samples to their corresponding basal samples, we observed that the T and B cell responses (CD137+ B, CD137+ CD4, and CD69+ B cells) were consistently more pronounced and significant in controls than in MS patients (Figures 5B, G–I; Supplementary Table 8).